Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.23.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]  
Summary of Subsidiaries The Company’s subsidiaries and its interests in each are presented below as of December 31, 2022:
 
Name of Entity
  
Place of Incorporation
  
Interest
 
MPX Bioceutical ULC (“MPX ULC”)
(1)
   Canada      100
MPX Luxembourg SARL
(1)
   Luxembourg      100
ABACA, Inc.
(1)
   Arizona, USA      100
Ambary, LLC
(1)
   Arizona, USA      100
Health For Life, Inc.
(1)
   Arizona, USA      100
iAnthus Arizona, LLC (“iA AZ”)
   Arizona, USA      100
S8 Management, LLC
(1)
   Arizona, USA      100
S8 Rental Services, LLC
(1)
   Arizona, USA      100
Soothing Options, Inc.
(1)
   Arizona, USA      100
The Healing Center Wellness Center, Inc. (“THCWC”)
(1)
   Arizona, USA      100
Bergamot Properties, LLC
   Colorado, USA      100
Scarlet Globemallow, LLC
   Colorado, USA      100
iAnthus Capital Management, LLC (“ICM”)
   Delaware, USA      100
GHHIA Management, Inc. (“GHHIA”)
   Florida, USA      100
GrowHealthy Properties, LLC (“GHP”)
   Florida, USA      100
iAnthus Holdings Florida, LLC (“IHF”)
   Florida, USA      100
McCrory’s Sunny Hill Nursery, LLC (“McCrory’s”)
   Florida, USA      100
iA IT, LLC
   Illinois, USA      100
Budding Rose, Inc.
(1)
   Maryland, USA      100
GreenMart of Maryland, LLC
(1)
   Maryland, USA      100
LMS Wellness, Benefit, LLC
(1)
   Maryland, USA      100
Rosebud Organics, Inc.
(1)
   Maryland, USA      100
Cannatech Medicinals, Inc.
(1)
   Massachusetts, USA      100
Fall River Development Company, LLC
(1)
   Massachusetts, USA      100
IMT, LLC
(1)
   Massachusetts, USA      100
Mayflower Medicinals, Inc.
   Massachusetts, USA      100
Pilgrim Rock Management, LLC
   Massachusetts, USA      100
CGX Life Sciences, Inc. (“CGX”)
(1)
   Nevada, USA      100
GreenMart of Nevada NLV, LLC (GMNV)
(1)
   Nevada, USA      100
iAnthus Northern Nevada, LLC
   Nevada, USA      100
GTL Holdings, LLC
   New Jersey, USA      100
iA CBD, LLC (“iA CBD”)
   New Jersey, USA      100
iAnthus New Jersey, LLC
   New Jersey, USA      100
MPX New Jersey, LLC
 (1)
   New Jersey, USA      100
Citiva Medical, LLC (“Citiva”)
   New York, USA      100
iAnthus Empire Holdings, LLC
   New York, USA      100
FWR, Inc.
(2)
   Vermont, USA      100
Grassroots Vermont Management Services, LLC
(2)
   Vermont, USA      100
Pakalolo, LLC 
   Vermont, USA      100
 
(1)
Entities acquired as a part of the MPX Bioceutical Corporation (“MPX”) acquisition on February 5, 2019 (the “MPX Acquisition”).
(2)
Entities in Vermont - the sale agreement for the business in Vermont was executed on February 6, 2023.
Summary of Cash And Cash Equivalents Restricted Cash And Restricted Cash Equivalents The following table summarizes a reconciliation of cash and restricted cash reported within the consolidated balance sheets to such amounts presented in the statements of cash flows:
 

 
  
As of December 31,
 
 
  
2022
 
  
2021
 
Cash
   $  14,336      $  13,244  
Restricted cash
     70        3,334  
    
 
 
    
 
 
 
Total cash and restricted cash presented in the statements of cash flows
  
$
14,406
 
  
$
16,578
 
    
 
 
    
 
 
 
Summary of Property Plant And Equipment Useful Life
Property, plant and equipment are recorded at historical cost net of accumulated depreciation, write-downs and impairment losses. Depreciation is calculated on a straight-line basis over the estimated useful life as follows:
 
Buildings
  
  
20 - 25 years
     
Leasehold improvements
  
  
over the shorter of the initial term of the underlying lease plus any reasonably assured renewal terms, and the useful life of the asset
     
Production equipment
  
  
5 years
     
Processing equipment
  
  
5 years
     
Sales equipment
  
  
3 - 5 years
     
Office equipment
  
  
3 - 5 years
     
Land
  
  
not depreciated
Summary of Effects Of the Adjustment On The Line items Within Consolidated Financial Statements
The effect of the adjustments on the line items within the Company’s consolidated balance sheet as of December 31, 2021 is as follows:
 
 
  
December 31, 2021
 
 
  
As previously reported
 
  
Adjustment
 
  
As adjusted
 
Inventories
  
$
30,447
    
$
(1,755
  
$
28,692  
Current assets
     55,401        (1,755      53,646  
Total assets
     346,744        (1,755      344,989  
Accrued and other current liabilities
     99,446        (513      98,933  
Current liabilities
     285,821        (513      285,308  
Total liabilities
     369,141        (513      368,628  
Accumulated deficit
     (800,390      (1,242      (801,632
Total shareholders’ deficit
     (22,397      (1,242      (23,639
Total liabilities and shareholders’ deficit
     346,744        (1,755      344,989  
The effect of the adjustments on the line items within the Company’s consolidated statements of operations as of December 31, 2021 is as follows:
 
 
  
Year Ended December 31, 2021
 
 
  
As previously reported
 
  
Adjustment
 
  
As adjusted
 
Costs and expenses applicable to revenues (exclusive of depreciation and amortization expense)
  
$
(91,735
  
$
(1,755
  
$
(93,490
Gross profit
  
 
111,283
 
  
 
(1,755
  
 
109,528
 
Loss from operations
  
 
(22,025
  
 
(1,755
  
 
(23,780
Loss from operations before income tax
  
 
(53,999
  
 
(1,755
  
 
(55,754
Income tax expense
  
 
22,249
 
  
 
(513
  
 
21,736
 
Net loss
  
 
(76,248
  
 
(1,242
  
 
(77,490
Earnings per share
  
 
(0.44
  
 
(0.01
  
 
(0.45
The effect of the adjustments on the line items on the Company’s consolidated statement of cash flow for the year ended December 31, 2021 is as follows:
 
 
  
Year Ended December 31, 2021
 
 
  
As previously reported
 
  
Adjustment
 
  
As adjusted
 
Net loss
  
$
(76,248
  
$
(1,242
  
$
(77,490
Change in operating assets and liabilities
  
 
16,594
 
  
 
1,242
 
  
 
17,836
 
The effect of the adjustments on the line items within the Company’s consolidated statements of changes in shareholders’ (deficit) equity for the year ended December 31, 2022 is as follows:
 
 
  
December 31, 2022
 
 
  
As reported
 
  
Adjustment
 
  
As adjusted
 
Accumulated deficit – Balance January 1, 2022
  
$
(800,390
  
$
(1,242
  
$
(801,632
Total shareholders’ deficit – Balance January 1, 2022
  
 
              (22,397
  
 
(1,242
  
 
(23,639
Summary of Effect Of The Adjsutment On The Line Items Within Inventories
The effect of the adjustment on the line items within the Company’s inventories as of December 31, 2021 is as follows:
 
 
  
Year Ended December 31, 2021
 
 
  
As previously reported
 
  
Adjustment
 
  
As

adjusted
 
Supplies
  
$
6,188
 
  
$
—  
 
  
$
6,188
 
Raw materials
  
 
5,641
 
  
 
215
 
  
 
5,856
 
Work in process
  
 
11,219
 
  
 
(1,970
  
 
9,249
 
Finished goods
  
 
7,399
 
  
 
—  
 
  
 
7,399
 
  
 
 
 
  
 
 
 
  
 
 
 
Total
  
$
30,447
 
  
$
(1,755
  
$
28,692